246 related articles for article (PubMed ID: 26898341)
1. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.
Ferraz MJ; Marques AR; Appelman MD; Verhoek M; Strijland A; Mirzaian M; Scheij S; Ouairy CM; Lahav D; Wisse P; Overkleeft HS; Boot RG; Aerts JM
FEBS Lett; 2016 Mar; 590(6):716-25. PubMed ID: 26898341
[TBL] [Abstract][Full Text] [Related]
2. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.
Ferraz MJ; Kallemeijn WW; Mirzaian M; Herrera Moro D; Marques A; Wisse P; Boot RG; Willems LI; Overkleeft HS; Aerts JM
Biochim Biophys Acta; 2014 May; 1841(5):811-25. PubMed ID: 24239767
[TBL] [Abstract][Full Text] [Related]
3. Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders.
Ferraz MJ; Marques AR; Gaspar P; Mirzaian M; van Roomen C; Ottenhoff R; Alfonso P; Irún P; Giraldo P; Wisse P; Sá Miranda C; Overkleeft HS; Aerts JM
Mol Genet Metab; 2016 Feb; 117(2):186-93. PubMed ID: 26750750
[TBL] [Abstract][Full Text] [Related]
4. Lyso-glycosphingolipids: presence and consequences.
van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
[TBL] [Abstract][Full Text] [Related]
5. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease.
Aerts JMFG; Kuo CL; Lelieveld LT; Boer DEC; van der Lienden MJC; Overkleeft HS; Artola M
Curr Opin Chem Biol; 2019 Dec; 53():204-215. PubMed ID: 31783225
[TBL] [Abstract][Full Text] [Related]
6. Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes.
Squillaro T; Antonucci I; Alessio N; Esposito A; Cipollaro M; Melone MAB; Peluso G; Stuppia L; Galderisi U
J Cell Physiol; 2017 Dec; 232(12):3454-3467. PubMed ID: 28098348
[TBL] [Abstract][Full Text] [Related]
7. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
8. Alpha-galactosidase A in vascular disease.
Bodary PF; Shayman JA; Eitzman DT
Trends Cardiovasc Med; 2007 May; 17(4):129-33. PubMed ID: 17482095
[TBL] [Abstract][Full Text] [Related]
9. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
[TBL] [Abstract][Full Text] [Related]
10. Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
Lelieveld LT; Gerhardt S; Maas S; Zwiers KC; de Wit C; Beijk EH; Ferraz MJ; Artola M; Meijer AH; Tudorache C; Salvatori D; Boot RG; Aerts JMFG
J Lipid Res; 2022 May; 63(5):100199. PubMed ID: 35315333
[TBL] [Abstract][Full Text] [Related]
11. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.
Karageorgos L; Hein L; Rozaklis T; Adams M; Duplock S; Snel M; Hemsley K; Kuchel T; Smith N; Hopwood JJ
Neurobiol Dis; 2016 Jul; 91():143-54. PubMed ID: 26976737
[TBL] [Abstract][Full Text] [Related]
12. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease.
Batta G; Soltész L; Kovács T; Bozó T; Mészár Z; Kellermayer M; Szöllősi J; Nagy P
Sci Rep; 2018 Jan; 8(1):157. PubMed ID: 29317695
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and novel treatments for sphingolipidoses.
Arenz C
Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617
[TBL] [Abstract][Full Text] [Related]
15. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
16. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
[TBL] [Abstract][Full Text] [Related]
17. Neuropathic pain in a Fabry disease rat model.
Miller JJ; Aoki K; Moehring F; Murphy CA; O'Hara CL; Tiemeyer M; Stucky CL; Dahms NM
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563343
[TBL] [Abstract][Full Text] [Related]
18. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
19. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
20. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
